SPONSOR
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
Conditions studied: B7-H3-positive Relapsed/ Refractory NeuroblastomaCD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaSystemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic SclerosisIgG4 Related DiseasePrimary Sjögren Syndrome
NCT05562024 Phase 1
Recruiting
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
B7-H3-positive Relapsed/ Refractory Neuroblastoma
NCT07188610 Phase 2
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
NCT06361745
Recruiting
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Systemic Lupus Erythematosus